OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
240
Results
Show all
Save search
Copy query
Show results for
Unknown
(238)
Proteomics
(2)
Organisms
Homo sapiens
(1)
Mus musculus
(1)
Repository
pride
(2)
Tissue
Cell culture
(1)
Liver
(1)
Technology Type
Data-independent acquisition
(2)
Mass Spectrometry
(2)
Publication Date
2025
(1)
2024
(1)
Release Date
2021
(37)
2023
(31)
2022
(28)
2020
(26)
2025
(25)
2024
(22)
2019
(14)
2018
(14)
2015
(10)
2017
(7)
2026
(5)
2013
(5)
2016
(4)
2014
(4)
2011
(3)
2012
(2)
2009
(1)
Lab affiliation
Bradley Distinguished Professor Chair of Cancer Biology & Research Professor of Cell Biology Centre for Cancer Biology University of South Australia
(1)
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
(1)
Previous
page
1 / 24
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
24
Next
page
Sort
by:
Relevance
Page size
10
A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development.
Not available
S-EPMC10481129
|
biostudies-literature
Cite
Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1).
Not available
S-EPMC6987634
|
biostudies-literature
Cite
Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin.
Not available
S-EPMC7846644
|
biostudies-literature
Cite
Safety and Efficacy of Switching SAR341402 Insulin Aspart and Originator Insulin Aspart vs Continuous Use of Originator Insulin Aspart in Adults With Type 1 Diabetes: The GEMELLI X Trial.
Not available
S-EPMC11571405
|
biostudies-literature
Cite
Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial.
Not available
S-EPMC7336880
|
biostudies-literature
Cite
Drug-related problems and challenges encountered by pharmacists in nirmatrelvir/ritonavir counselling during the covid-19 pandemic: a multi-center study.
Not available
S-EPMC12484732
|
biostudies-literature
Cite
Prevalence of visual impairment and its causes in adults aged 50 years and older: Estimates from the National Eye Surveys in Malaysia.
Not available
S-EPMC11500914
|
biostudies-literature
Cite
Assessing the colony morphotypes and antibiotic susceptibility profile of Malaysian clinical Burkholderia pseudomallei to support the use of EUCAST disk diffusion breakpoints to determine antibiotic resistance.
Not available
S-EPMC10822001
|
biostudies-literature
Cite
Hyperinflammatory syndrome resembling haemophagocytic lymphohistiocytosis following axicabtagene ciloleucel and brexucabtagene autoleucel.
Not available
S-EPMC10661175
|
biostudies-literature
Cite
Magnetic nanoparticles assisted dispersive liquid-liquid microextraction of chloramphenicol in water samples.
Not available
S-EPMC7211875
|
biostudies-literature
Cite
Previous
page
1 / 24
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
24
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
